Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211

S. Z. Usmani, R. Sexton, Sikander Ailawadhi, J. J. Shah, J. Valent, M. Rosenzweig, B. Lipe, J. A. Zonder, S. Fredette, B. Durie, A. Hoering, B. Bartlett, R. Z. Orlowski

Research output: Contribution to journalLetter

22 Scopus citations
Original languageEnglish (US)
Article numbere334
JournalBlood Cancer Journal
Volume5
DOIs
StatePublished - Aug 7 2015

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Usmani, S. Z., Sexton, R., Ailawadhi, S., Shah, J. J., Valent, J., Rosenzweig, M., Lipe, B., Zonder, J. A., Fredette, S., Durie, B., Hoering, A., Bartlett, B., & Orlowski, R. Z. (2015). Phase i safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211. Blood Cancer Journal, 5, [e334]. https://doi.org/10.1038/bcj.2015.63